Literature DB >> 21190649

Strategies for improving treatment adherence in schizophrenia and schizoaffective disorder.

Donald C Goff1, Michele Hill, Oliver Freudenreich.   

Abstract

Nonadherence with medication treatment is common but difficult to detect in patients with schizoaffective disorder and schizophrenia, almost half of whom take less than 70% of prescribed doses. Like patients in all areas of medicine, patients with schizoaffective disorder weigh the perceived benefits of medications against perceived disadvantages, but this process is complicated by their impaired insight, the stigma of the diagnosis, and the often troubling side effects of antipsychotic medication. Interventions to improve adherence include encouraging acceptance of the illness, drawing analogies with treatment for chronic medical disease, and involving the patient in decision making. Clinicians must remain nonjudgmental, encouraging patients to disclose problems with adherence and anticipating that improvement in adherence may require a prolonged effort. Selection of antipsychotic medication is critical to avoid adverse side effects, and some medications may provide a sense of well-being, such as improvement in insomnia, anxiety, or depression. Depot (rather than oral) antipsychotics can improve adherence and provide the clinician with reliable information about the dosage of medication received, which can be used for purposes of dose adjustments or to guide response to relapse. © Copyright 2010 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21190649     DOI: 10.4088/JCP.9096su1cc.04

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  34 in total

1.  Avoiding risk with nonadherent patients.

Authors:  Ann McNary
Journal:  Innov Clin Neurosci       Date:  2015 Mar-Apr

2.  Adherence with general healthcare among internal medicine outpatients with mental health treatment histories.

Authors:  Randy A Sansone; R Jordan Bohinc; Michael W Wiederman
Journal:  Innov Clin Neurosci       Date:  2015 Mar-Apr

3.  Optimal sampling of antipsychotic medicines: a pharmacometric approach for clinical practice.

Authors:  Vidya Perera; Robert R Bies; Gary Mo; Michael J Dolton; Vaughan J Carr; Andrew J McLachlan; Richard O Day; Thomas M Polasek; Alan Forrest
Journal:  Br J Clin Pharmacol       Date:  2014-10       Impact factor: 4.335

Review 4.  Oral paliperidone: a review of its use in the management of schizoaffective disorder.

Authors:  Lily P H Yang
Journal:  CNS Drugs       Date:  2011-06-01       Impact factor: 5.749

Review 5.  Using incentives to reduce substance use and other health risk behaviors among people with serious mental illness.

Authors:  Jennifer W Tidey
Journal:  Prev Med       Date:  2011-12-09       Impact factor: 4.018

6.  Factors Associated with Adherence to the HEDIS Quality Measure in Medicaid Patients with Schizophrenia.

Authors:  Marie-Hélène Lafeuille; Christian Frois; Michel Cloutier; Mei Sheng Duh; Patrick Lefebvre; Jacqueline Pesa; Zoe Clancy; John Fastenau; Mike Durkin
Journal:  Am Health Drug Benefits       Date:  2016-10

7.  Cost-Minimisation Analysis of Paliperidone Palmitate Long-Acting Treatment versus Risperidone Long-Acting Treatment for Schizophrenia in Spain.

Authors:  Javier Quintero; Itziar Oyagüez; Beatriz González; Ignacio Cuervo-Arango; Ignacio García; Miguel Angel Casado
Journal:  Clin Drug Investig       Date:  2016-06       Impact factor: 2.859

8.  A randomized trial comparing in person and electronic interventions for improving adherence to oral medications in schizophrenia.

Authors:  Dawn Velligan; Jim Mintz; Natalie Maples; Li Xueying; Stephanie Gajewski; Heather Carr; Cynthia Sierra
Journal:  Schizophr Bull       Date:  2012-10-19       Impact factor: 9.306

9.  Nurses' perceptions of medication adherence in schizophrenia: results of the ADHES cross-sectional questionnaire survey.

Authors:  Robin Emsley; Koksal Alptekin; Jean-Michel Azorin; Fernando Cañas; Vincent Dubois; Philip Gorwood; Peter M Haddad; Dieter Naber; José Manuel Olivares; Georgios Papageorgiou; Miguel Roca; Pierre Thomas; Ludger Hargarter; Andreas Schreiner
Journal:  Ther Adv Psychopharmacol       Date:  2015-12

10.  Extended-release intramuscular paliperidone palmitate: a review of its use in the treatment of schizophrenia.

Authors:  Natalie J Carter
Journal:  Drugs       Date:  2012-05-28       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.